The estimated Net Worth of Christine Anna White is at least $82.6 Tausend dollars as of 6 September 2019. Christine White owns over 15,000 units of MEI Pharma Inc stock worth over $45,300 and over the last 18 years Christine sold MEIP stock worth over $37,269.
Christine has made over 2 trades of the MEI Pharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Christine bought 15,000 units of MEIP stock worth $26,100 on 6 September 2019.
The largest trade Christine's ever made was selling 18,728 units of MEI Pharma Inc stock on 13 June 2016 worth over $37,269. On average, Christine trades about 1,249 units every 44 days since 2006. As of 6 September 2019 Christine still owns at least 15,000 units of MEI Pharma Inc stock.
You can see the complete history of Christine White stock trades at the bottom of the page.
Christine's mailing address filed with the SEC is C/O MEI PHARMA, INC., 11455 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, 92130.
Over the last 12 years, insiders at MEI Pharma Inc have traded over $26,282,680 worth of MEI Pharma Inc stock and bought 597,450 units worth $2,541,200 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Leaf Ventures Ii, L.P.New L... und Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $360,383. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth $329,211.
mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.
MEI Pharma Inc executives and other stock owners filed with the SEC include: